SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending as the cannabis sector rallies on reports of potential federal rescheduling, with buzz building around a possible executive order from President Trump. Community members are weighing the potential implications for tax relief, banking access, and institutional investment, while also debating optimal strategies given the stock's history of volatility. Bullish sentiment is strong, tempered by caution around past disappointments.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending due to speculation of an imminent short squeeze, fueled by its low float and recent AI and blockchain deal. Community chatter suggests a potential for significant upward movement, with some comparing it to other recent low-float runners. Traders are closely watching key breakout levels, anticipating a rapid price surge if volume increases.

GhostwareOS (GHOST) is the Full-Stack Privacy Layer of Solana — a next-generation AI-driven infrastructure for encrypted communication, anonymous identity management, and untraceable transactions. By combining advanced zero-knowledge protocols with autonomous AI routing, GhostwareOS allows users and developers to operate invisibly across Web3. It powers decentralized apps that demand true digital anonymity, scalable privacy, and zero metadata leakage — restoring control to users in an overexposed internet age.

Ghost

Ghost is trending as the community anticipates the launch of GhostPay. Social media buzz compares Ghost to other cryptocurrencies and highlights its potential for significant gains. Community members are actively encouraging others to join and are sharing contract addresses.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending due to its AI and Autonomy Day, where the company showcased its new in-house AI chip and self-driving capabilities, sparking discussions about its competitive positioning against Tesla. The community is actively debating the potential for a short squeeze and the implications of Rivian's technology roadmap, with some analysts raising their price targets on the stock.

The Mosaic Co. engages in the production and marketing of concentrated phosphate and potash crop nutrients. It operates through the following segments: Phosphates, Potash, and Mosaic Fertilizantes. The Phosphates segment is involved in the ownership and operation of mines and production facilities which produce concentrated phosphate crop nutrients and phosphate-based animal feed ingredients, and processing plants which produce concentrated phosphate crop nutrients. The Potash segment includes mining, processing, and selling potash. The Mosaic Fertilizantes segment focuses on mines, chemical plants, crop nutrient blending and bagging facilities, port terminals, and warehouses. The company was founded on March 25, 2004 and is headquartered in Tampa, FL.

Mosaic Company

Mosaic Company is trending as investors weigh the impact of potential potash production cuts by Belarusian producers, which could support global pricing and benefit fertilizer companies; however, some analysts remain cautious about the stock's recent performance and potential headwinds from tariffs. Community discussions also highlight the stock's valuation and potential for a turnaround, with some pointing to the company's long-term potential in the agricultural sector amid concerns about food security.

Advisorshares Trust - AdvisorShares MSOS 2x Daily ETF

AdvisorShares MSOS Daily Leveraged ETF

MSOX is trending due to speculation around potential cannabis rescheduling, fueled by recent hints and rumors. The community is discussing potential overnight price surges and comparing MSOX to other cannabis stocks, expecting substantial gains if rescheduling occurs. Some traders are expressing caution, while others remain confident, anticipating a significant rally in the cannabis sector.

Loopring is a Decentralized Exchange (DEX) built on an Ethereum Layer-2 (L2) solution called zkRollup. It has both Automated Market Maker (AMM)-based and orderbook-based exchanges.   zkRollup is an Ethereum L2 scaling solution that migrates computations off the blockchain. Loopring protocol only uses the underlying Ethereum blockchain as a data layer and a verification layer. As a result, Loopring's throughput is as high as 2,025 trades per second compared to Ethereum’s current throughput of 15 transactions per second. The result is that the cost per trade settlement is as small as $0.00015.  Loopring's performance is sufficient for professional traders and market makers to deploy algorithmic strategies and other automated trading bots. This was not previously possible on any DEX as it was prohibitively slow and expensive. By building on top of Loopring 3.0, orderbook-based DEXs can be commercially viable for the first time. Loopring expects non-custodial exchanges can begin to outcompete and displace many centralized counterparts.

Loopring

Loopring is trending as the crypto market shows signs of a potential rally, with community members discussing AI-related catalysts like project "PROMPT" and its connection to Nvidia. Bullish sentiment is building, with some traders eyeing a potential short squeeze and others pointing to inverse head and shoulders patterns as indicators of an upcoming price surge. Community members are actively monitoring Loopring's chart, anticipating a breakout toward higher price targets.

Bank of America Corp. is a bank and financial holding company, which engages in the provision of banking and nonbank financial services. It operates through the following segments: Consumer Banking, Global Wealth and Investment Management (GWIM), Global Banking, Global Markets, and All Other. The Consumer Banking segment offers credit, banking, and investment products and services to consumers and small businesses. The GWIM segment focuses on solutions to meet clients’ needs through a full set of investment management, brokerage, banking, and retirement products. The Global Banking segment deals with lending-related products and services, integrated working capital management and treasury solutions to clients, and underwriting and advisory services. The Global Markets segment includes sales and trading services, as well as research, to institutional clients across fixed-income, credit, currency, commodity, and equity businesses. The All Other segment consists of asset and liability management activities, equity investments, non-core mortgage loans and servicing activities, the net impact of periodic revisions to the mortgage servicing rights valuation model for both core and non-core MSRs, other liquidating businesses, residual expense allocations and other. The company was founded by Amadeo Peter Giannini in 1904 and is headquartered in Charlotte, NC.

Bank Of America Corp.

Bank of America Corp

Bank of America is trending as traders discuss its potential after recent highs, comparing it to the 2008 crash period and other banks like Wells Fargo. Discussions include option strategies, potential pullbacks after reaching all-time highs, and the overall health of the banking sector amidst market volatility. Some are pointing to analyst ratings and upcoming catalysts, while others express concern about overbought conditions.

Tidal Trust II - YieldMax COIN Option Income Strategy ETF

YieldMax COIN Option Income Strategy ETF

YieldMax COIN Option Income Strategy ETF ($CONY) is trending due to discussions around its dividend payout and reverse split. The community is debating the impact of these factors on the ETF's overall value and questioning the management of YieldMax ETFs in general. Some investors remain optimistic about $CONY's potential, particularly with positive movement from Coinbase ($COIN), while others express concerns about NAV erosion.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is trending as community members highlight its potential as a high-speed, compliance-focused Layer 1 solution for institutional finance. Discussions emphasize Keeta's recent integration with Bridge, enabling seamless fiat on/off-ramps, and its impressive transaction throughput. Community members view Keeta as a foundational layer for global financial plumbing, positioned to complement established networks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Analysts said Medicare’s drug-price cuts were smaller or already reflected in forecasts.</li><li>Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.</li><li>Retail traders on Stocktwits turned extremely bullish on LABU as message volume surged.</li></ul>The biotech sector rallied sharply on Wednesday after Wall Street analysts said the latest round of U.S. Medicare drug-price cuts would have a smaller impact on pharmaceutical companies than initially feared, lifting the Direxion Daily S&amp;P Biotech Bull 3X Shares ETF (LABU) to its highest level in nearly 20 months.The&nbsp;<a href="https://stocktwits.com/symbol/LABU">LABU ETF</a> extended its rally on Wednesday, rising 3.7% to close at $165.5 and edging up 0.2% after hours, marking its fourth straight session of gains.<h2 class="st-heading-2">Bernstein Says Semaglutide Pricing Is ‘Final Cloud To Clear’</h2>Shares of major drugmakers jumped after the U.S. government published negotiated Medicare prices for 15 drugs late Tuesday, with cuts of up to 85% scheduled to begin in 2027.Novo Nordisk’s U.S.-listed shares rose&nbsp;nearly 4%, and Teva Pharmaceuticals gained over 5%, after their flagship therapies appeared on the pricing list. Novo’s semaglutide drugs, Ozempic and Wegovy, along with Teva’s Austedo, were included among the treatments subject to reductions.Bernstein analyst Christian Moore said the negotiated price for Novo’s semaglutide was “the final cloud to clear on the drawn-out, but positively resolved GLP-1 pricing debate,” Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novo-shares-rise-us-medicare-price-cuts-come-largely-expected-2025-11-26/">reported</a>.<h2 class="st-heading-2">Goldman Sachs Says Austedo Cut Milder Than Expected</h2>Goldman Sachs analyst Matt Dellatorre noted that Austedo’s 38% price cut came in lower than the roughly 45% reduction modeled. He said the updated government price, which is a little over $700 lower per monthly supply versus one estimate of its net price, was below expectations and therefore less damaging for Teva.<h2 class="st-heading-2">Guggenheim Flags Deeper Than Expected Cuts For AbbVie</h2>Guggenheim analyst Vamil Divan said AbbVie’s cuts on Linzess and Vraylar, which come up to 75% and 44%, respectively, were deeper than anticipated.Two analysts said they are now watching how Medicare plans will manage access to the first batch of 10 drugs whose new negotiated prices take effect in January 2026, and what the Feb. 1 announcement of the next 15 drugs for 2028 will reveal.<h2 class="st-heading-2">Bernstein, William Blair, And Others Say Impact Already Priced In</h2>Bernstein analysts said five of the 15 targeted medicines will be generic by 2027, limiting exposure to deeper cuts. They added that lower prices could keep patients on branded therapies longer, potentially supporting volumes.William Blair analysts said the $274 monthly Medicare price for Novo’s semaglutide broadly tracks recent government agreements but added that insurance-coverage expansion remains uncertain. Analysts also said reductions had already been reflected in forecasts for Novo Nordisk, AstraZeneca and GSK.&nbsp;Earlier this month, Novo said it expected a low single-digit global sales impact if pricing were implemented this year, which analysts indicated translates to roughly DKK 6 billion.<h2 class="st-heading-2">Liquidity Wave Drives LABU Frenzy On Stocktwits</h2>On Stocktwits, retail sentiment for LABU was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:970/143;" src="https://news.stocktwits-cdn.com/labu_ss_png_d696fb5c91.webp" alt="labu ss.png" width="970" height="143"><figcaption>LABU sentiment and message volume as of November 26 | Source: Stocktwits</figcaption></figure>One user said, “This concentrated burst of purchasing power is pushing up prices.”<stembedurl>https://stocktwits.com/JesusHolbrook/message/637590765</stembedurl>Another user said the move looks close to a blow-off top, possibly around $165–$175, and warned that any pullback could echo the sharp drop seen after the Covid peak.<stembedurl>https://stocktwits.com/bottomfishtrader/message/637525624</stembedurl>The LABU ETF has risen 22% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The LABU ETF has risen 22% so far in 2025. (Photo credit: Getty Images)

Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared

Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.

Equity

Best-Performing Leveraged ETFs of October 

October's top ETF gainers included the likes of NVTX, AMUU, KORU, LABU and INTW. These ETFs soared as AI, crypto and reform optimism drove markets higher.

<ul class="summary-bullets"><li>The agency approved the medicine for both adults and pediatric patients with acute myeloid leukemia who are 1 year or older and have a susceptible nucleophosmin 1 (NPM1) mutation.</li><li>In the second quarter, Revuforj achieved $28.6 million in net revenue, representing a 43% increase over the first quarter of 2025. &nbsp;</li></ul>The U.S. Food and Drug Administration on Friday said that it has approved Syndax Pharmaceuticals’ (SNDX) Revuforj for some relapsed or refractory acute myeloid leukemia (ACL) patients with particular mutations.The agency <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation">approved</a> the medicine for both adults and pediatric patients one year and older with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options. &nbsp;<h2 class="st-heading-2">Implication For Patients, Syndax</h2>According to Syndax, mutations in the NPM1 gene are the most common genetic alteration observed in AML, occurring in approximately 30% of adults with the condition. Patients with the mutation have a poor prognosis, and there are currently no approved therapies that selectively target the underlying disease mechanism driving the cancer, it said.Revuforj was launched in the U.S. in November 2024 for the treatment of a specific type of leukemia called relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. The new FDA approval expands the indication for the drug.In the second quarter, Revuforj achieved $28.6 million in net revenue, representing a 43% increase over the first quarter of 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company soared 4% on Friday morning at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SNDX">SNDX stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume improved from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:583/60;" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAkcAAAA8CAYAAABsOR7cAAAQAElEQVR4Aex9DVyUVdr3f2CI4SMYMHXG1Q1WMyFtw9xN2e1pnV7bV1jfFPoSXu1N0lLMdwtrd8vH7deP6reFtY/50Wro5j6QfYgViT264s/KrzLN8gHzo8GVmgmRQRQZBOG5rns+mIEZmOFLwGt+95n7Pte5ruuc85/7/s91n3PumYBmeQkCgoAgIAgIAoKAICAIOBEIgLwEAUFAEBAEBIEBiYB0ShDoHAISHHUON7ESBAQBQUAQEAQEgQGKgNfg6NKlBlRXn0dFRRV++OGMJMFAzgE5B/w6B5g7mEOYS7rKn63t2Sf75jqEn4Sf5RyQc8Cfc4B5g/mDeaQ1tzjyHoMjNrJYaqBWqxEVFQG9/joMGzZYkmAg54CcAz6dA8wZzB3MIcwlzCkO0unqnn2xT/bNdXBdwk/Cz3IOyDngyznAfMG8wfzBPMJ84omTAloLz549p4iGDIlGeHgIgoLUUKlUikzeBIGuISDWVwsCKpVK4Q7mEOYS7reDW/i4s8nhg32yb+GnziIpdoLA1YmASuUbN7kFRxxBBQYGQKu9VgKiq/O8kV4LAt2OgEqlUjiFuYU5prMVsC37EH7qLIJiJwgIAq4IqFTeuckZHPHcW339JURGhrvaejwWoSAgCAgC/iLA3MIcw1zjry3bsC378NdW9AUBQUAQaA8B5hXmF+YZh54zOLp40YqwsFAZMXIgI3tBQBDoVgRUKpXCMcw1/jpmG+Enf1ET/U4iIGZXGQIqVVtucgZHHDEFBwddZZBIdwUBQaA3EWCOYa7xt062YVt/7URfEBAEBAFfEGB+YZ5x6DqDo8bGy1CrAx1y2QsCgoAg0O0IMMcw1/jrmG3Y1i87URYEBAFBwEcEmF+YZxzqzuCIBSqVPJXGOEgSBASBnkFApeo8x6hUnbftmd6IV0FAEBgoCKhU7vziFhwNlE5KPwYUAtIZQUAQEAQEAUGgVxGQ4KhX4ZbKBAFBQBAQBAQBQaCvI9B7wVFfR0LaJwgIAoKAICAICAKCACHQh4Ojy6g4fQaN1EjZBAFBQBAQBDwhUI49m/fhtKcikfUqAlLZwEKgy8FRbelWrHttNV5bRWnNe/jk9OVOI1T1XQlMdXbz6i+wvaAYn1fb8z21qzPjyHeWnvIufgWBHkGguRmoq6vH+fMXYbGcR2VlNfjPFM3mszCZzlCqxI8/nsWZMxbwX26cO3cBFy7UwfVR1R5pWB9yWrH7baxav8s9cDi1C+tefxt7zvShhtqb0ni4EKsKS+w52+7c/vfw5k6zLePx3YIfysyo8lgmQkGg9xEYKNzUteCo6Rts3VaDm+bMx2MLKD2QgGEBnf05gBoc/ewASh3BkHYi0v///UjU9vCH+69D2HmwvIcrEfeCQNcRaGhoRE1NrRLwXLp0CefOnafgqJaCJKsS9PBjqE1NTWByaqa3y5ebwDb8y6+1tXVkewG852DJYqkhu3rSpSir603rkx4u19dD3XAKX5a2NO/0t+Wwoh7WxhaZ+9GVy6lH6xFZdhJHmxxtqMfRk2cQPUznEMheEOiTCDDPDDRu6lpwRORT7/pRRYzEqJ/YBU0WHN68AateX4tVa9/Dnu9t8qNb3kbxV7uxce1avPYfa5G3x3ZXxPIvibD/ezPpbzlGysdQ+PpWHKUjgI7/sxj7i9/DmhUr8CrJD/9YgsL17GO1251V7Yldim+udx35qWX7M/uQV3gAR7ZQe9h+7TYc5REqlm8/icbvP6N29s27SW6+pKsbAQ56qqpqlKDowoWL9oCnAcHB1/gNzDXXXAMOlnjUiQMkHm3igIliKb999QcDtTYUVceO2Zt6CkdMYRgSipZX7UkUb1xH1z/xznriG4UwANNu4ppVJHt9HTZ+Wq5M73uSVX21FW8Sl63ikfMNu2ByBDbf73PyEHPRKsdolZf6lAaFjMOoQeU4flzJ0dDgNzhxNgY33Ej5JouNT7lNqzagsPQiCVttzGf/uQ8VdjGPnOXttg2R8XHh7m/wvoMzqU+nP6U+Mh++XojD9n7DUU8r3ra7lJ0g4IbAQOamrgVHIRNgmAB8uW4t3txyAKdrWnA7uuU9HBk2HQsenYsFqXoc37EP56i4vu4Mjp6KwtSMuXhsVjwavzykBEBjkqfhpvAI3DSD9JNHsybqadrAFnzVo/5MOSp+moR5Cxdiqr4MxR+Zccv/ZR83A0dsPlC1D+/tvIgJ/498UL2JjbtQ/C25aiT7sm9RdXM6FrD9kJPYf5AaO3gi0m8fDvzk19ROGqUaTLqyDQgEBkInLl++TFNmNcp0mdVquxIc/eIApzPBUUCrK55Hl3jKjYMkDpgc/gfM/robEVNZgsMctHxL0/b66xHd4OidBXs27ULthAfp+ifOmNiI4mIOpEqw/wBwG3HIgkcfwNSfD4canmRAsD4B04nLFtDI+ZTIEmzbS7yCMyj+uASRU8gn+bhrRDBGTGZ+8Vafoz3BGHN9BE4bT9kEx8pRFTMSYyh3dMtGfBlmwLwF5PPBBNTu2Iw9refSmOfohtWxsIFHzurrbTk+LjtVj3970M6ZBwqx/9q77Hxajq++4nYD3nibmiCbIOBE4GrgplZU6ey7zwf6X92PBfOmYSy+pZGc1bCNBJ2C8ftgRASexJcHD+HLMiDsohm0A7+GxMQjkmuOjkAYX9As7DBF4KejbLd8kdeGITI2HiOCyCi6xUf9iVOojQzFuW+oTqq3NigUZ763jUwhdDhuGBFIBgDbX673cOellMqbIHDlETh/vhY//lilTH15ag0PYwcFqT0VeZWp1YE0/eZ5PslBdrx2ie8GvTrpdwWDccvoWpQevIijR6sQM07f0oO6kzBeIP6o+drGU3XBCKswwQQ9Rgy1YPfGYhppCkRkBJt4kgFhQwfjclkJPvm4EF9VAjZe4YCEfCl2pBPciJpzFNx6rY/921LkTSMR9q+Tyjqpo/86gxGjRlMB82kYYhI4SKNs2Djccn0NjCfIJ2V93cJ0wxEdQNrMmdTHG26xNbCFD7meYK+8DXkJAoTA1cJNfKlQd7u4BetwazKNytw9ErVffw0j6tHovDtj36GI/WUCRvChX8k/ZWtDK+LXxeOXN0b550S0BYEriAAHJryImhdad9QMDmgCA32/hHmkiUec2vN76VIDuP7aWp53bk+z/5RFjxuJyyd24EhtDG5xiY1Q3wh3xhiMsRNvRDSicOsDc/DAxAgYt9FU/OYSYjRPsos4/N6b2Fqmxpjbk3BHbJgdFB1uSwjG4U1v4/3Nb2PrDyNphD0Y3uuzm/FOG48bNDS1ZjqG46cGI5an1Kj2xoZAaIJYwZaCg9TEsf4FRzbL9t6vDG+31yIp6zsIXG3cFNAl6M8eQPHnrZ70CgqGBtdj2OAa1DTdiFvHJ9jSLdcT6XRUWyMuN3Wk4708crge6up6RN/iqDMBY38S7N3AUdKFOh0uZC8IdBUBDkwqKy3KmiJffNXX+7fuKCgoCExwHflubm4GT7VVV5/vSLV/lGsTMKqJRpVHxLtzkHY4hqlrUB9t5wvmqjgdgnER52oCEf2zCZj24EQMoZGc4x5lJ3HcNBi3GkZjSFggauscwUoNDpdcxq2p0zH5zumYM/sO6JlpvdbnCmMExsQG4vRumgLUjcTP2U7hUwuMx+yj3dSXo/8KxLDhEa6GwNBohF6woELhs4uoqKx1L+8wd30nebtDx6LgDYF+Ir8auUm59Dr9+WiigBPv4bUVvHBxLV776Axi75wIPdHLrdPuQsThN7Fqw/t4b8M6rPv4WKu7tNa16hD3MzWOFr2NvA8O4FzrYl/y1xsw7SYLtq7agDy6Y1u35m3sOduB4ejRiK3chzfz30bxiQ50pVgQ6CEEeL0PT2k1NTX7XEN9/SW/FmU3Nyvfmj77v3jRqvwMQDMFSz4b9UnFYNyWSiNBvyK+cmvfcExJjkfVx6uxLr8QeevXIm8f3eydKcHWjWttstx9qL35FxjrSYaRuEFvRvGb7yPvzTyU1oXavUdgxJBa7M8nHqK0av3bKPz0JGrhpT64v6JvigFOlyP6hnH2gmC08Gke1q3ahqqbkjDlei4ORXCQCUf2nwECRmPsT00o5kXbr29GRVg0K/iRXOvxlbf9cC+q/RKBq5WbuhYchY2EIW0uHnskHelps/HYwnRMibGP1ISNxrS58zEv1YCpM+dgTtJoqAH8/J6FuOfndKBs43DP49PhyOonz8b8tKmYnjQBkXAtcz0G9IbZmGPQKR7gpkdlvAZqwf34Hd+xPXo/EgeRmv4OzMm4g4I2OqbNzT4kHtMfnY3pv5sOwygqlE0Q6GUEeAqLnxzzt1peTB0cHITIyHBERUXguuu0GDIkGnr9dUriY5ZxmVZ7LXgazt86OADjR//7Y4Dkdp0HUxARwL3XwZAxGwY9H1P6yUSkPzof6b+7A/c8OBfpiRRADZ6AB+bNxey778D02XPx4GQd4EmGUOKzuciYYcA9s9Ix7Z50Gy81HcNX3w/HdF48/ehczLtvIjTHdmO/yUt9JHbbon+FBx935UkqDRtt59NpSCe/6b+iNoFfIzHtkQfxu7EcCAVj7Iz5WDD7fmTMS6fA735be0jNDYvWnOnKp856DG68TS5kuwoRuJq5SaGLLn/mQaGIjAj26EYdFoGwII9FHoX+6nt0EhDstT3w9PJX35MPkQkCnUCAR2d4Cssf09BQjRIIcRAUEBCAsLAQhIQE45prgqBWB0KlUimJj1nGZWwTERGOwYOjEB4eCn/WKvGQOgdI/rSxv+kGR0QgOMC91Z64yJOsjW19LU2xXURVNS/MBi7XmFBxOQpDtC3+29i0FLV7xPW3bieYf8MCnXad9e10QAdcjz+8TSayDTAErnZuakUHA+zTle4IAv4g0Mu6vP7Hn8CIF1QPHRoNLY0CcdDTmeYGBakRERGGoUMH0T5cCaLgw4sDJP6RNx9URSUkAfekXo+KXUV4f3Mhth5W498emIaxIQKNINA/EBBuAiQ46h/nqrRygCHA01RVVed8+oVqHh2KiroWgwZF0ohPYLchER4egiFDonxet8Q/QMnTbN3WgAHsSD00AVNnTMN0Tv97AkZEDODOStcGFALCTbaPM8C2G1Dv0hlBoM8jwCNGfHfWUUPVNE3GU2EhIZqOVDtVHhgYqARdPDXniwOL5Tx4rZMvuqIjCAgC/Q8B4SbbZybBkQ0HeRcEeg2BpqYmWK2XOqyPp844MAoM7PnLlBd1+xIgcdvr6qwdtl0UBAFBoKcQ6Dm/fH0LN9nw7XnWtdUj74KAIGBHgH/deujQaGUhtV3UZseBEU+jqVSqNmU9JegoQFKr1TTKpMW5pjp8V2XuqWaIX0FAELhCCAg3tQAvwVELFnIkCPQ4Akw+/OQX/6YRP0XGj9tzIORaMY8URUdH+rxY2tW2q8ccIPHCb1c/AQEqsDw8KhSv7S/E/1r7NHI+2eSqIsedQEBMBIG+hIBwk/unIcGR3sQDRgAAEABJREFUOx6SEwR6FAHH34IwEXGAxP9TFBUVgejoCOdia85zQNKjDWnHObeF1zqxCk+1DR4SjY+NB2FY80es2vsR6hsb8F/fHoRRRo8YIkmCwIBAQLjJ/WPscnBkrTTDbG6VqvvXmgTj6mToRyRjpeOfcd0x8ppz73s1/O118RN6qncxipUairF4BOWfsOVwYiUSo6KQvL796YvOtl2pUt66AQHfXfACbKu13s2grq4eFRVVaGi4jMGDtTRtFan8XpGbUi9nVCoVBWuRypNsxtoKzPhHNp7ckouKCy2/W9+MZqzeV9TLLfOzOmt1W24yV8Pq/odqfjrtbfVid17wtXp7392p2Ipq5mqH0EeOUaosW4lk4qfk1UYlK28DCwHhprafZxeDIyNWTtZDr2+VFhW3rclVolxo/gcjri669fiCEeZyo5+k2brvUQihL5V4Cm6qfWycElyVm+xBlRWmcgoyK60t1laX4xap+5GfbX/22Wdx3333ufuQXK8gwD+q5qkifnSWR5D4D19bT7F50u8NGY8cvXFgG1IoMDpi9nzXUFi6Hxcb3IO93mibz3Vsz2zLTfrEDm+ClJsWuo59rqdHFT3wgi/12fueud1VuRiZzNWu/OwLx7CLRiuMxE/GC5zxLQnX+IZTX9ASbmr7KXQxOLI7HPMM9phMMDnScoO9wMuuvBTFfgcjXnx1k7jTbpx9/w47noxD6avJWPJZp721GI7KxJ66Omx5SNci64YjJqz4+HgJkLoBS39deCMghx8OSFQqlSPr055HbX/7298q65MCAwPxpz/9iUahGhRbDrqOHTuG3//+9wgNDcVf/vIXRe7r21id8uddXtV5eu2fxw95Le8rBSkbXLjJtAeZMe21zAzjV61uUtpT789lPcQxDkiEaxxI9P19T3BTbW0tFi1apHCTSqVCYmIiysvLFTD6Azd1T3CkjoJOp2tJWg3M/0jFz0bEY+FW2+iHeX0qTSElI/etxdBPW0mjJaVYcrueZLZpJWV66K6V2LtzMeKDVFClFRCIVpS+RnacJ3BDEkjXPiyj6E96HgWbH7bpU3nii4dg3rcEiSFkT3n9nCLY1QGu0YsvKnRu1q0LlXYvdglwSl9MhJ7rtnXFqascOPseC0NKErRUj/U8lJfSxhHUZiVHb9up7zQ0vXg7HXe0KaNrejiHscvzkT7C1i9VkB53Li1GS98A09bFThzc+402LyGtNpD0uODSpQbwY7LtVRQeHtZecZuyxsZGPP744zhx4gT27duHDz74AH/729+Qm5ur6F68eBFLly5Ffn4+6ijQVoR+vP065iaM1bUbSeCj0s/98HhlVDVaF27SaaFp3IslvyDuIb5RJokovzhOj/FP5eOvSQlYuBPAW+nETY7rr1iZ2lpYWIrcJD2RfTyeP0o6lUVYnBBCebou6ZpMXVtKQt5s+g+vLcYyRZ/K9anIp5GX/NlsT/mgRCxjH7C/vPqylys7Gq02ULtTcmFW8vR2oQAPE6ckr3VKSOjj1ppjGql/Kfb2EX9GkV89JScHsdsz1Oc4aj+Vq/QPo8iVhLi8VRKuaQXIlct6rbknuIkr27hxI/7+979j165dyvQ237y99NJLXIT+wE3dExxVHkTRuwUoUNIh5cLVzcpBpq4UKxdk45C1GNkLCmCdsQQZt6dj5dxJBJAOKU+vxMpX0hFPOfD00PaFSEzbg6Tlm7DpiURUv5WK+EXFSFxTApNxB7LUy3DnfXZiYH0KhFKfAjLz85A5Adj79Hjo7z0Ew5pNyJmhhXl9BnIOsHO078umorxrpqQgqZLane+YGjyEvOV7UT0pCQaNouL+5uj7P5YhddYyVE/IQdYUuwq3sdwxbUYyq4mm78wwWem4o63RfRi76Ol05KszscVownfbFiOBSKvlr5pKsWx5NeHg6Hdqh6NXzz77LGQEqaMPofvKrR38rlFgYACCg4P8qvDs2bP4/PPPkZGRgdtuuw3Jycm4++67sZFI6cKFCwgLC1OOt27dCh458su5Xfn+m2+3H3ne7T5VgqbmZs+FfURq/NTBTQUoPkoXn2YSljyXDCvxzcK3qmFenUWBSjwyF6Xgt48vQYqOGj4xg7hpJbIm6yljVaa8V/4fCorCFyNvwwqkjTpEAVYylqmzsIOuyZI1iSiel4jF+0Avm37uvFQUTViGTS+lQGsuQPqIWGRrlmDThkwkNO7FYgrGqDVAY3u+yJ1zi0XqjFiYN+dik+0GHNbCXOSWxyJpKjfaqeg8cO17wbvFMDpL6KDRnWNKCZOHN8djxfE61H2TjVgK5qKmZtsxIH3aSl8mjlu0yd6nXKQu3UvS9jfhmvbxudKlPcFN3KfKykrceOONGDduHIYOHYqJEyfi5MmTsNJUblg/4KbuCY7M+Vh4XypSlZSDg4wMYpH1j2zElT2P1ISHsRJpyHuBgqLhCUi5PZY0ojB+agpS7k2AjnK2TUNf8HuQM5/kFOxsWlsE0ChT3kNx0MUYkP10GrC92O4f9IpDztY3kHlvGlZwGUnSVm1B9qwUZD2URDkaIud/woYZHfsidd7UBmQ+GQvr+gIUN5LgyCbkmzXISDNQxsNGpJf9RCYyn85GwQlAp7HA5Me8vAeP3kVmI4yVgH5yFnLmxrnoOXCgfj+dCR2ssFhciuXwiiPQ0MAnk/dm8B/Dei/1XBJI02gajQY//PCD829IhgwZAqPRiPPn7cOXnk19lv4u7pcIVHmnibqGSzh5VrnIfPbZ24p7X3ZwUyoWFtraqpmag9yZGhQtSISBvuDjXnoDGcM1iJuShPHXUQtjDcRNKTCM0VDGvk1cgT3vZCFtlgGx+3KxrEyHZ1ZnwxCjQ9xD2Vg8phpFn7qEH7PysOO5NKQ8yWXkY2w2tqzJRMqsLKSPpTwFVUprfPFF6rzpHlqIFOxF3mYeKbLSDSlx5OQMpA7n0rbJte+p9y0jy7Y6DomxjNo+NglJozTQjE1T2lhKPO6KQdxLO/AG8/OTS+jmF7BWC9E48Ouv+57gJsbirrvuUoKhP/zhDzhy5Ag+/fRTzJw5ExriLC7vauppbvLOev60fGwOvqO7R55HbG7OQ5LDdkwmsqYCxqNGJLy0DEnhjgJv+1jEjnCUGVHKyxkK05WFziqVCqqUfEdh2726rahF4p+vuHlZmGRdidytgHFrAYyaDKT/usWb2xER3p7TJphOW9Bs2QTDgedx55x8Ck/ctLqcSVq+A1ljirGQpgNCQsZj8c5qzz61UYjyXOIm5bu5kpISvPPOO25yyfQMAg0NDe06bv3bQu0q2wsHDRqEKVOmYPXq1bj33nvxm9/8Bq+++qq9tHt2kZowxA/9abvO/vvHU+2WX+nCtA+bleCR+amEbnxs7dEiZVEmtNWlKL2QgRWP8w2brcTr+w2xcNzIVR8vhRVmPP8L4iXmJlU8lrhOk7k50UDTDj/55Ss8DZnzNdi7Jg/GxmJs2QwYZibD0S63ainj2vfm5i2g20uSet7G324AjuRi5U4jjDuJ/44AKZMTPStDi6jr4NNLuMYnmK6YUk9wE3fm5ptvxvz587F27Vpl9Cg8PFwZ2eay7kg9zU3dExx56+lnS7B4axwMkzU4tDQbe9u/eW7lRQf9KBJNy0OdM/BiksuDM/iiYt82P30NT0XGZCD/3VwUbS2F7vEMTPKlIi3dhbLicQqWnPrVqO6OkSStATmH6lBn2oHsSTSNZshAfif9Clk5P5xeOeD/Imtqanatq81xUJC6jawjgUqlwrJly/Dhhx9i2LBheOqpp8CfLf+SdUBA913aHS3MPnrmdEdN7YPlZuQ+vQzWyQbENebi+Q5+MqN1B7S6WBLRyNEXzc7Ayz34omIfN399GdIyoKEgpmB9EQqIDTNm6nysqX013b2ZSKGR7wIaTUtccAiJ60qQN1PTvlEHpXw+yk1YByBdweKe4ia+Fpibdu/eDZ7+37ZtG/jhkLS0tE6tf/QGUU9yU/cwqGPdzbv2uf3tdFfF8+izVsI6KwdbaI7eUL0S6Ut5KIi6qQ6ht1Js2lwKs7kayrw7Sdy3WKTPMwCFmUhfX4pqmqesPkJkcMCztrtt65xvviwXHL51SJ+bAry7kEZodMhISWjtsCXfaKE+mGE+Uoz8pemkD2inJCKWNEK0enovRt5b1E8is9R5+ZRvvVndgycr4dEmiKxG0dLFyD1gBnQUgE1gv9bWjnzKx8TEQMjKJ6i6TampqaldX2p1IFQqVbs63gp5ai05ORnLly+HwWDAJ598gjFjxiAyMtKbid/yMYOdw7kebStrazzK+4rQfd1NAQ6VA9VvZeDhnXHIXrMDuY9pUTwvA/mOwVgNtXx7AYrKzO7XJomd25QMZGpp5Gj+EhSXW2G9YMahd1ut6XEqd3Dgiy+rCy/8OhNZMaVYsigX1mnpSAnvwL+Pxca1S1Bwy2Js+cIEU+kOvPFQHBgKH83bqMUI17TBpK8JeoqbampqUFBQgKlTpyI6OloZ4X7xxRexZ88elJWVdRsMPclNAd3SSrc1R6lIfaIIn76cjufLiHyWJkEzPAMrXoiD8cVULOEF0lOykDMB2PtUPPT6dBR4GQHRzd2EHY/rUTAnHlEhIYgal4rsgkOwdqLR7fmKnZqOOJTieQrmjHbfGrqLyqSarDEZSKe22sXuO84dfR6J/Nsh4+5E+stGjP/3LTC+xMNHgG5mFjJ0VhTNo34mLEPsc8/ANcwyzEghDwVIX1BEewNS76Xdu+nIoOk8OmrZrERWZUV4mKfUVCFIfLkOSWtykBbeouLrEZ+YMpXmK1rdo9cRAXVllIfvyPjptFOnTuGvf/2rMq//yCOPKPP6VVVVyhNs//znP3Hp0iV8/fXXSp7l/vRscFj7gVZVnZcL2J9KelB3r8uao9T7UpHzWQEy5xRBQzdumTQ6Pem5XKRpipA+Ox/ViEXG0jRozblIjtUj7gX7DR1avdSTsGLvG0gqp2n0ESEIuVaP8U+sxN4y+P9q15cnXojDwicmgRe2psxMQVcCGNfGKjy4bzHir1VBpbInfTJyj7pq+X5cVlYm0/a+w3VFNHuKm4KDg8HT/h999BEqKiqU0aLt27eD10RysMQc9MEHH6Avc1MXg6NYZH3T7DaszMNpzd9kYcqfSkhegiwiH/7U45T8d8jmQEMdh6wv6mAxmWA5vwX8JR/7pLs+2wBaGF4heZ0FJpMFdQ11OPjCJIUM2ujT9BvXnTcNtlfrPLz7wthnUHKe6tiZCR7xgcsrdhYHTi4C56GHvtd9hx3PJUHrmCEJT8IbpjrqJ7W9rgQ5c7NxkKYIHW3UzNiEOosJluUG8qpByjs23ZVTKDsqCyWkq6yR0MQhY4MrDiZssS/IboOD3c5RB3mS7Qoj0NTBlFpAgKpTLeTznR/j53n9GLpL//Of/4yXX34Z06bZLgJemM3D2H/84x/Bj/3zI/2cZ7k/FUaHXtuuuuXi+XbLr1ihnQMYJ9nSfMwAAAT4SURBVNeU90AK8uqaUbchSeESaG355g8pKAKxDtlZmA+Ic4wvJJAkCXl0LTaTPmVatjEZ2GIiP2dMMFnq0Hx6E9JiuLi1fqyNJ4kXY7mYWEbhTWeehF59adx5gVRbthSkTtO0ZF2PqA/cZ3ceSHLvh50rFI4B3cS9kgPrkzuIa6k/Jkrf5GCSuQjLCumW0U2XK4q19ak1Jlwkqd8g0BE3dZabeNE1r3+sr69XnlTjp2WLiorwyiuvKHnmIOaivsxNAVfuU9RAq9NBG46OXxotdDptu4saO3Zi1/DmK5zquE5DSmbsfWsZFt+eqjxhl/NEHMm6smmgbaftGi1hoOV6QS+NouvMotVLQ21sx1crbcn2EQRCQoIxbNhgryk6uv2RGW/dUKlUWLBgAfjH1n788Udlz3mVyhZs3XrrrYqMvyQdiXVZ7s2nJ/kvR4zGd39Y5zVtnv3vnsz6tyzcfq350AvNdTrovF60PjhwUfHsSwPmEKWKryhYoZGwxEV7aVQrW7mxRLe8DqHorWpYzNWgyhS+RelBGk/XInGsvltqECd9D4Ge4ibu6ejRo5WfGrFYLKisrARzFE+zcRlzEHORg5d4z3mWc7mvqSe56QoGR752v7f1SrDpqRzkNSbhjS9ykaLt7fqlPkHAPwSCgoKU4Wre+2cp2v0NAePelchZXopYmr7f86SvN26+9HISsouewfidqdArP6IbgtinzcgoKMUbUzW+OBAdQcAjAlqtVpliU6lsN20elfqgUIKjNh+KATn8aP4XecgYK6TQBh4RCAKCwBVDIHb+FphOl7hP33dTa7STs7HjdDP4Lp5T3fEdyJmh6ybv4kYQ6F8ISHDUvz4vae1VjIB0XRAQBAQBQaB3EJDgqHdwlloEAUFAEBAEBAFBoJ8g4BYc8VBqP2l3P26mNF0QuHoR6ArHdMX26kVcei4ICAK+INCaX5zBEf8QXWPjZV98iI4gIAgIAp1CgDmGucZfY7ZhW3/tRF8QEAR6GYF+Wh3zC/OMo/nO4Oiaa4JQX9/gkMteEBAEBIFuR4A5hrnGX8dsw7b+2om+ICAICAK+IMD8wjzj0HUGR6GhGtTWXlSeVHAUyl4QEAQEge5CgIetmWOYa/z1yTZsyz78tRX9TiEgRoLAVYMA8wrzC/OMo9PO4IgjpuDga3DuXN/+KwBHw2UvCAgC/QsB5hbmGOYaf1vONmzLPvy1FX1BQBAQBNpDgHmF+YV5xqHnDI5YoNVei8uXm1BdfV5GkBgQSYJAf0egD7Sf78qYU5hbmGM62yS2ZR/si3121o/YCQKCgCDACDCPMJ8wrzC/sMyR3IIjFg4aZPsrg4qKKly4UIeGhkYJlBgYSYKAIOAzAkw6zB3MIcwlbOjgFj7ubHL4YJ/sm+vgujrrT+wEAUHg6kKA+YJ5g/mDeYR77+AVPnakNsERF3AEFRUVofxZpcVSA5OpEj/8cEbSlcNAsBfs+9U5wJzB3NHY2AjmEuYU5pbuSOyLfbJvroPrEn4SfpZzQM4BX84B5gvmDeYP5hHmE0+85DE4YkWee2OjIUOivf5hZnt/pillgwW3dv5sVc6PgX9+MHcwhzCXMKd0Z2Kf7JvrkHNp4J9L8hkP9M+4d/vHvMH8wTzijZe8BkfeDEQuCAgCgoAgIAgIAoLAQEZAgqOB/OlK3wQBQUAQ6EUEpCpBYKAg8D8AAAD//0t1vHAAAAAGSURBVAMAWenBlxreIIEAAAAASUVORK5CYII=" width="583" height="60" alt="SNDX's Sentiment Meter and Message Volume as of 1:39 p.m. ET on Oct. 24, 2025 | Source: Stocktwits"><figcaption>SNDX's Sentiment Meter and Message Volume as of 1:39 p.m. ET on Oct. 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes the stock is a good buy below $20.<stembedurl>https://stocktwits.com/dcrown/message/633624243</stembedurl>Another raised doubts about the possibility of a major rally.<stembedurl>https://stocktwits.com/Olena/message/633527864</stembedurl>SNDX stock is up by 15% this year but down by about 20% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/teladoc-stock-shoots-up-bofa-views-it-as-differentiated-asset-but-cautious-on-near-term-outlook/cLGJuuUR3ti">Teladoc Stock Shot Up 8% Today: BofA Views It As Differentiated Asset But Remains Cautious On Near-Term Outlook</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval 

The agency approved the medicine for both adults and pediatric patients with acute myeloid leukemia who are 1 year or older and have a susceptible nucleophosmin 1 (NPM1) mutation.

Leveraged ETF Areas of Last Week That Are Up At least 15%

Tech rally, weak jobs data and Fed rate cut bets were highlights of last week. Winning leveraged ETFs were GDXU, SOUX, AVGG, GGLL and LABU.

LABU
Direxion Daily S&P Biotech Bull 3X Shares

Feed

News

Sentiment

Fundamentals

Info

Latest LABU News

LABUDirexion Daily S&P Biotech Bull 3X Shares